Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Clinicians can generally assume CD38 expression is maintained on myeloma cells without repeat testing. However, performing a bone marrow biopsy at relapse is critical to confirm BCMA expression and identify emerging resistance mechanisms before choosing BCMA-targeted engagers.

Related Insights

In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.

To determine why a BCMA-targeted therapy failed, clinicians are using plasma sequencing assays to check for mutations in the BCMA receptor. The presence of a mutation prompts a switch to a different target rather than retrying a BCMA-directed agent.

As frontline therapies improve and create longer remissions, the first relapse becomes the pivotal moment for treatment. Experts advocate for treating this stage with the same intensity and goals as newly diagnosed disease, including aiming for MRD negativity.

Target antigen loss or modulation on tumor surfaces is a frequent mechanism of resistance following CD19 CAR-T or CD20 bispecific antibody failure. Dr. Budde highlights that treating relapsed patients with further targeted therapy without a biopsy frequently leads to treatment failure, as tumors often become CD19- or CD20-negative. Re-biopsying is vital to confirm target presence before initiating next-line therapies.

A convergence of data from pivotal trials (MAJESTIC, CARTITUDE) establishes that BCMA-directed therapies, including CAR-T and bispecifics, provide superior outcomes in early relapse. This marks a paradigm shift, making them the new standard of care after initial therapy failure, even in patients refractory to prior common treatments.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

Clinicians report significant and durable responses using Belantamab in patients who have relapsed after BCMA-targeted CAR-T. This success may be due to Belantamab's immunogenic mechanism, which doesn't rely on endogenous T-cells and may favorably interact with the post-CAR immune environment.

The introduction of ADCs, bispecific antibodies, and CAR-T therapies has rendered established myeloma treatment pathways obsolete. Clinicians can no longer rely on familiar triplets at first progression. This rapid evolution requires a complete rethinking of sequencing, described by the speaker as putting the old algorithm 'into a blender.'

Performing dual analysis with both liquid and tissue biopsies at metastatic diagnosis establishes a comprehensive baseline. This strategy helps differentiate between clonal and later-acquired mutations, enabling more accurate interpretation of subsequent ctDNA monitoring for resistance.

Because CD20 x CD3 bispecific antibodies require CD20 target engagement, antigen downregulation or loss is a primary resistance mechanism in patients experiencing early relapse. Dr. Elizabeth Budde highlights that verifying CD20 expression via repeat biopsy is clinically mandatory prior to initiating bispecific treatment or determining post-relapse therapy, ensuring the target antigen remains present on lymphoma cells.